Effectiveness of multimodality treatment for autoimmune limbic epilepsy.
We evaluated the outcome of multimodality treatment in autoimmune limbic epilepsy in 3 consecutive patients (2 male and 1 female; age 33-55 years) presenting with a combination of focal non-convulsive status epilepticus, memory impairment, and psychosis. MRI showed right or bitemporal T2 or FLAIR hyperintensity. Video-EEG showed seizures of right temporo-occipital or bitemporal independent onset. Extensive workup failed to reveal infectious aetiology or an underlying tumour. However, the autoantibody panel was positive for one or more of these antibodies: anti-VGKC, anti-GABAB, anti-VGCC (P/Q, N types), and anti-GAD65. All patients received: (1) conventional antiepileptic drugs including levetiracetam, lacosamide, phenobarbital, lamotrigine, and valproate; (2) immunomodulatory therapy including methylprednisolone, plasmapheresis, and intravenous immunoglobulin; and (3) rituximab. After a 4-6-week in-hospital course, the seizures resolved in all patients but 2 had persistent memory impairment. None had treatment-related complications. At the time of last follow-up, 2-3 months later, 2 patients remained seizure-free while 2 had residual memory impairment. Our findings suggest that multimodality treatment with a combination of conventional AEDs, immunomodulatory therapy, and rituximab is effective and safe in autoimmune limbic epilepsy.
['Dubey|Divyanshu|D|', 'Konikkara|John|J|', 'Modur|Pradeep N|PN|', 'Agostini|Mark|M|', 'Gupta|Puneet|P|', 'Shu|Francy|F|', 'Vernino|Steven|S|']
D000328:Adult D000927:Anticonvulsants D001327:Autoimmune Diseases D004359:Drug Therapy, Combination D004569:Electroencephalography D004827:Epilepsy D005260:Female D006801:Humans D007166:Immunosuppressive Agents D020363:Limbic Encephalitis D008297:Male D008875:Middle Aged D010257:Paraneoplastic Syndromes D013226:Status Epilepticus
status epilepticus rituximab autoimmune epilepsy limbic encephalitis paraneoplastic syndrome